



FORM PTO-1449/A and B (Modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 09/337,584		ATTY. DOCKET NO.: C1039.70020US01	
				FILING DATE: June 21, 1999		CONFIRMATION NO.: 9169	
				APPLICANT: Arthur M. Krieg et al.			
				GROUP ART UNIT: 1645		EXAMINER: Nita M. Minnifield	
Sheet	1	of	4				

U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
		5,023,243		Tullis	06-11-1991
		5,780,448		Davis	07-14-1998
		5,830,877		Carson et al.	11-03-1998
		5,985,847		Carson et al.	11-16-1999
		6,086,898		DeKruyff et al.	07-11-2000
		6,225,292	B1	Raz et al.	05-01-2001
		6,534,062	B1	Raz et al.	03-18-2003
		6,552,006	B2	Raz et al.	04-22-2003
		6,558,670	B1	Friede et al.	05-06-2003
		6,610,308	B1	Haensler	08-26-2003
		6,787,524	B2	Chang et al.	09-07-2004
		6,977,245	B2	Klinman et al.	12-20-2005
		6,994,870	B2	Tsai	02-07-2006
		7,129,222	B2	Van Nest et al.	10-31-2006
		7,306,782	B2	Borel et al.	12-11-2007
		7,514,414	B2	Klinman et al.	04-07-2009
		7,514,415	B2	Klinman et al.	04-07-2009
		7,521,063	B2	Klinman et al.	04-21-2009
		7,541,040	B2	Puri et al.	06-02-2009
		7,566,703	B2	Krieg et al.	07-28-2009
		7,605,738	B2	Kuramochi et al.	10-20-2009
		7,615,227	B2	Klinman et al.	10-10-2009
		7,713,529	B2	Krieg et al.	05-11-2010
		2001-0046967	A1	Van Nest et al.	11-29-2001
		2002-0028784	A1	Van Nest et al.	03-07-2002
		2002-0042387	A1	Raz et al.	04-11-2002
		2002-0055477	A1	Van Nest et al.	05-09-2002
		2002-0098199	A1	Van Nest et al.	07-25-2002
		2002-0102255	A1	Chang	08-01-2002
		2002-0107212	A1	Van Nest et al.	08-08-2002
		2002-0142978	A1	Raz et al.	10-03-2002
		2003-0125284	A1	Raz et al.	07-03-2003

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 09/337,584	ATTY. DOCKET NO.: C1039.70020US01
				FILING DATE: June 21, 1999	CONFIRMATION NO.: 9169
				APPLICANT: Arthur M. Krieg et al.	
				GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifield
Sheet	2	of	4		

		2003-0129251	A1	Van Nest et al.	07-10-2003
		2003-0130217	A1	Raz et al.	07-10-2003
		2003-0143213	A1	Raz et al.	07-31-2003
		2003-0147870	A1	Raz et al.	08-07-2003
		2003-0175731	A1	Fearon et al.	09-18-2003
		2003-0176373	A1	Raz et al.	09-18-2003
		2003-0176389	A1	Raz et al.	09-18-2003
		2003-0199466	A1	Fearon et al.	10-23-2003
		2003-0212028	A1	Raz et al.	11-13-2003
		2003-0216340	A1	Van Nest et al.	11-20-2003
		2003-0225016	A1	Fearon et al.	12-04-2003
		2004-0006010	A1	Carson et al.	01-08-2004
		2004-0009942	A1	Van Nest et al.	01-15-2004
		2004-0038922	A1	Haensler et al.	02-26-2004
		2004-0063880	A1	Chisholm et al.	04-01-2004
		2004-0064064	A1	Zhou et al.	04-01-2004
		2004-0132685	A1	Krieg et al.	07-08-2004
		2004-0136948	A1	Fearon et al.	07-15-2004
		2004-0247662	A1	Dow et al.	12-09-2004
		2004-0248837	A1	Raz et al.	12-09-2004
		2005-0013812	A1	Dow et al.	01-20-2005
		2005-0070491	A1	Krieg et al.	03-31-2005
		2005-0175630	A1	Raz et al.	08-11-2005
		2005-0209183	A1	Kippenberger et al.	09-22-2005
		2005-0209184	A1	Klinman et al.	09-22-2005
		2005-0261215	A1	Garren et al.	11-24-2005
		2005-0276756	A1	Hoo et al.	12-15-2005
		2006-0002959	A1	Glenn et al.	01-05-2006
		2006-0002962	A1	Jacobi et al.	01-05-2006
		2006-0019909	A1	Agrawal et al.	01-26-2006
		2006-0171968	A1	Brimnes et al.	08-03-2006
		2007-0243209	A1	Segal et al.	10-18-2007
		2008-0260751	A1	Karp et al.	10-23-2008

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 09/337,584		ATTY. DOCKET NO.: C1039.70020US01	
				FILING DATE: June 21, 1999		CONFIRMATION NO.: 9169	
				APPLICANT: Arthur M. Krieg et al.			
				GROUP ART UNIT: 1645		EXAMINER: Nita M. Minnifield	
Sheet	3	of	4				

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
		EP	1 671 646	A2	Dynavax Technologies Corporation	06-21-2006	
		WO	98/32462	A1	Wagner et al.	07-30-1998	
		WO	98/55609	A1	The Regents of the University of California	12-10-1998	
		WO	00/15256	A2	Pasteur Merieux Serums Et Vaccins [FR]	03-23-2000	Y-Abstract
		WO	00/61151	A2	The Government of the United States of America	10-19-2000	
		WO	01/22990	A2	Coley Pharmaceutical Group, Inc.	04-05-2001	
		WO	01/35991	A2	Dynavax Technologies Corporation	05-25-2001	
		WO	01/68116	A2	Dynavax Technologies Corporation	09-20-2001	
		WO	02/28428	A2	Aventis Pasteur [FR]	04-11-2002	Y-Abstract
		WO	02/069369	A2	Coley Pharmaceutical Group, Ltd.	09-06-2002	
		WO	03/043572	A2	3M Innovative Properties Company	05-30-2003	
		WO	2004/041183	A2	The Regents of the University of California	05-21-2004	
		WO	2006/080946	A2	Coley Pharmaceutical GmbH	08-03-2006	
		WO	2006/091591	A1	The Regents of the University of California	08-31-2006	
		WO	2006/096497	A2	Dynavax Technologies Corporation	09-14-2006	
		WO	2007/031877	A2	Coley Pharmaceutical GmbH	03-22-2007	
		WO	2007/038720	A2	Coley Pharmaceutical GmbH	04-05-2007	
		WO	2007/095316	A2	Coley Pharmaceutical GmbH	08-23-2007	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		[No Author Listed] Press Release, June 2006, "Cytos Biotechnology updates on development of allergy vaccine". 4 pages.	
		[No Author Listed] Press Release, January 2007, "Coley Pharmaceutical Group Updates Hepatitis C Drug Development Strategy". 1 page.	
		[No Author Listed] Press Release, June 2007, "Coley Pharmaceutical Group Announces Pfizer's Discontinuation of Clinical Trials for PF-3512676 Combined with Cytotoxic Chemotherapy in Advanced Non Small Cell Lung Cancer". 1 page.	
		[No Author Listed] CpG oligonucleotide adjuvants modulate allergic response in mouse model.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 09/337,584		ATTY. DOCKET NO.: C1039.70020US01	
				FILING DATE: June 21, 1999		CONFIRMATION NO.: 9169	
				APPLICANT: Arthur M. Krieg et al.			
				GROUP ART UNIT: 1645		EXAMINER: Nita M. Minnifield	
Sheet	4	of	4				

		Allergy Medicine, NewsRx.com. January 16, 2000. (Jahnschmid)	
		COOPER et al., Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine. 2004 Aug 13;22(23-24):3136-43.	
		CROFT et al., "Generation of Polarized Antigen-specific CD8 Effector Populations: Reciprocal Action of Interleukin (IL)-4 and IL-12 in Promoting Type 2 versus Type 1 Cytokine Profiles", J. Exp. Med., November 1994, Pages 1715-1728, Vol. 180, The Rockefeller University Press	
		FORNADLEY, Allergy immunotherapy. Otolaryngol Clin North Am. 1998 Feb;31(1):111-27. Abstract Only.	
		GOLDBERG et al., Beyond danger: unmethylated CpG dinucleotides and the immunopathogenesis of disease. Immunol Lett. 2000 Jul 3;73(1):13-8.	
		HOFFJAN et al., Toll-like receptors and airway disease. Drug Discov Today. 2006;3(3):317-24	
		JAROSZEWSKI et al., Cellular uptake of antisense oligodeoxynucleotides. Advanced Drug Delivery Reviews. 1991;6:235-50.	
		KLINKE et al., CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma. J Allergy Clin Immunol. 1999 Dec;104(6):1258-64.	
		KOU et al., [Analysis and regulation of interferon-gamma production by peripheral blood lymphocytes from patients with bronchial asthma] Arerugi. 1994 Mar;43(3):482-91. Japanese.	Y- Abstract Only
		LEUNG, Pathogenesis of atopic dermatitis. J Allergy Clin Immunol. 1999 Sep;104(3 Pt 2):S99-108.	
		MURAD et al., CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy. Expert Opin Biol Ther. 2007 Aug;7(8):1257-66.	
		QUDDUS et al., Treating activated CD4+ T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice. J Clin Invest 92(1):38-53, Jul. 1993.	
		ROJANASAKUL et al., Antisense oligonucleotide therapeutics: drug delivery and targeting. Adv Drug Deliv Rev. 1996;18:115-31.	
		THORNE et al., Experimental grain dust atmospheres generated by wet and dry aerosolization techniques. Am J Ind Med. 1994 Jan;25(1):109-12. Abstract only.	
		WEERATNA et al., Reduction of antigen expression from DNA vaccines by coadministered oligodeoxynucleotides. Antisense Nucleic Acid Drug Dev. 1998 Aug;8(4):351-6.	
		WEINER et al., Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10833-7.	
		YAMAMOTO et al., [Commemorative lecture of receiving Imamura Memorial Prize. II. Mode of action of oligonucleotide fraction extracted from Mycobacterium bovis BCG] Kekkaku. 1994 Sep;69(9):571-4. Japanese.	Y
		ZIMMERMANN et al., CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J Immunol. 1998 Apr 15;160(8):3627-30.	

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.